Aurinia Pharmaceuticals Inc

AUPHNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
15.84 USD
↘ 0.53 (3.24%)AT CLOSE (11:59 AM EDT)
15.88
↗ 0.04 (0.22%)
POST MARKET (AS OF 07:42 PM EDT)
Post Market
AS OF 07:42 PM EDT
15.88
↗ 0.04 (0.22%)
🔴Market: CLOSED
Open?$16.46
High?$16.70
Low?$15.82
Prev. Close?$16.37
Volume?1.3M
Avg. Volume?1.3M
VWAP?$16.17
Rel. Volume?0.97x
Bid / Ask
Bid?$13.73 × 100
Ask?$18.17 × 100
Spread?$4.44
Midpoint?$15.95
Valuation & Ratios
Market Cap?2.0B
Shares Out?128.6M
Float?109.8M
Float %?82.6%
P/E Ratio?6.83
P/B Ratio?3.59
EPS?$2.32
Dividend?0.00%
Ex-Dividend?N/A

Aurinia Pharmaceuticals Inc (AUPH) is currently trading at $15.84. The stock presents a bullish profile across the board: both technical indicators and our fundamental models signal a "Strong Buy" and "Buy" respectively. Notable factors include a robust Altman Z-Score, exceptional Return on Equity (52.5%) and a bullish Golden Cross on the moving averages. Valuation metrics place AUPH at a fair price relative to peers.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Themes
Biotech - Drug Development›Immunology & AutoimmuneBiotech - Drug Development›Rare Disease Therapeutics
Employees
128
Market Cap
2.0B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.auriniapharma.com
Listed
2009-10-21
Address
#140, 14315 - 118 AVENUE
EDMONTON, A0 T5L 4S6
Phone: 250-744-2487
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?
77
Z-Score?
100
Momentum?
73
Short Sent.?
54
Piotroski F-Score?6/9Mixed
Altman Z-Score?8.20Safe
Confidence?68%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?8.22%Elevated
Short Interest?9.0M
Days to Cover?6.8
Free Float109.8M
Avg Daily Volume1.3M
Settlement Date2026-05-15
Financial Health
Current Ratio?5.55Strong
Quick Ratio?5.01Strong
Cash Ratio?0.47Low
Debt/Equity?0.11Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
72/100
P/E?
Peers
100
S&P
97
6.8CHEAP▾
P/B?
Peers
100
S&P
48
3.59FAIR▾
P/S?
Peers
100
S&P
18
6.83FAIR▾
P/FCF?
Peers
100
S&P
82
12.2CHEAP▾
EV/EBITDA?
Peers
100
S&P
45
15.8FAIR▾
EV/Sales?
Peers
100
S&P
20
6.91HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
91
52.5%STRONG▾
ROA?
Peers
50
S&P
97
41.2%STRONG▾
Cash Flow & Enterprise
FCF?$166.6M
Enterprise Value?$2.1B
Fundamentals ratios updated end of day
MarketsMoversWatchlist